Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
M. D. Anderson Cancer Center to investigate chemokine antagonist for breast cancer
March 23rd, 2006
Chemokine Therapeutics Corp. (CHKT; CTI) announced that it has entered into an agreement with M.D. Anderson Cancer Center of Houston, Texas to study the company's lead anticancer compound, CTCE-9908, a chemokine CXCR4 antagonist. Oncologists at M.D. Anderson Cancer Center will study the benefits of CTCE-9908 in studies investigating the drug's ability to inhibit the metastasis of a human breast cancer in preclinical models. In previous experimental studies, CTCE-9908 has been shown to reduce cancer metastases by a considerable 50-70%. The CXCR4 receptor is present on most human tumors cells, including lung, breast, prostate, colon, ovarian, bone,...
Source: Women's Health Weekly (2006-03-23)
|
